Clinical evaluation of 3-day tebipenem pivoxil therapy in children with community-acquired pneumonia.
Hiroshi SakataPublished in: The Japanese journal of antibiotics (2018)
A 4mg/kg dose of tebipenem pivoxil (TBPM-PI) was administered twice daily for 3 days to 34 pediatric patients with pneumonia who had chest X-ray findings indicative of pneumonia and CRP values of at least 3.0 mg/dL. The clinical effects of this regimen were evaluated by retrospectively examining medical charts for the period from April 2012 to March 2015. The patients were 6 months to 8 years old, with serum CRP values ranging from 3.06 to 14.25 mg/dL. Fever resolved within 24 hours and respiratory symptoms improved within 3 to 5 days after the start of treatment in all 34 patients. Although CRP was positive in 28 of 30 patients at the end of the treatment period, none of these children showed worsening of pneumonia. Eight patients (23.5%) experienced adverse drug reactions including diarrhea. These results indicate that a 3-day course of TBPM-PI is useful for treating pediatric pneumonia.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- community acquired pneumonia
- healthcare
- prognostic factors
- adverse drug
- young adults
- magnetic resonance
- high resolution
- bone marrow
- patient reported outcomes
- stem cells
- clinical evaluation
- mesenchymal stem cells
- smoking cessation
- respiratory tract